|
US 12,454,549 B2 |
|
| Treatments for diseases and disorders that involve oxidative stress |
| Hampar L Karageozian, San Juan Capistrano, CA (US); Vicken H Karageozian, San Juan Capistrano, CA (US); and John Y Park, Santa Ana, CA (US) |
| Assigned to Jenius Pharma, LLC, Henderson, NV (US) |
| Filed by Jenius Pharma, LLC, Henderson, NV (US) |
| Filed on Jun. 6, 2023, as Appl. No. 18/206,415. |
| Application 16/882,656 is a division of application No. 16/012,706, filed on Jun. 19, 2018, abandoned. |
| Application 18/206,415 is a continuation in part of application No. 16/882,656, filed on May 25, 2020, abandoned. |
| Claims priority of provisional application 63/350,373, filed on Jun. 8, 2022. |
| Claims priority of provisional application 62/521,984, filed on Jun. 19, 2017. |
| Prior Publication US 2024/0132542 A1, Apr. 25, 2024 |
| Int. Cl. C07K 5/09 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/185 (2006.01); A61K 38/05 (2006.01); A61K 38/06 (2006.01); A61K 38/07 (2006.01); A61K 38/08 (2019.01); A61K 38/12 (2006.01); A61K 47/20 (2006.01); C07K 5/062 (2006.01); C07K 5/083 (2006.01); C07K 5/093 (2006.01); C07K 5/097 (2006.01); C07K 5/103 (2006.01); C07K 5/12 (2006.01); C07K 7/06 (2006.01); C07K 7/64 (2006.01) |